Ireland
--:--IST
Recruiting Phase 2

Subjective Experience Following Psilocybin

NCT06768944 · tracked via the Priya Life Science Canada tracker
Phase
Phase 2
Started
2026-05-15
Last updated
2026-09-02

Condition(s) studied

Investigating the Importance of the Subjective Psychedelic Experience

Investigational drug(s) / intervention(s)

Psilocybin high-dose →Psilocybin low-dose →Risperidone 1 MG →Placebo

Psilocybin high-dose: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose

Psilocybin low-dose: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose.

Risperidone 1 MG: risperidone 1mg capsules

Placebo: inactive placebo

Study summary

The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects of psilocybin.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Individuals of all sexes, gender identities, and ethnicities * Ages 18 to 65 years of age at the time of screening * Ability to read/write in English * Agree not to consume psychoactive drugs 24 hours before dosing sessions or consume psychedelics during duration of study participation Exclusion Criteria: * Any notable abnormality on electrocardiogram or routine medical blood or urinalysis laboratory tests * Current psychiatric diagnoses, such as: major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, moderate to severe substance use disorders, eating disorders, personality disorders, post-traumatic stress disorder * Lifetime or current psychiatric diagnoses of: psychosis, schizophrenia, bipolar disorder * Family history: a first- or second degree relative with a history of schizophrenia or other psychotic disorders, bipolar I or II * Medication: Any medication with the potential to interact with the investigational medicinal products, especially those with serotonergic mechanisms of actions like SSRIs, SNRIs or MAO-Inhibitors as well as other antipsychotics * Currently pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study * Current or recent (within 12 weeks) participation in a clinical trial involving medication administration * Cognitive impairment (Folsetin Mini Mental State Exam score \< 24) * A disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery). * Suffered a traumatic brain injury with one of the following symptoms Loss of consciousness \>30min Alteration of consciousness/mental state \>24h Post-traumatic amnesia \>1 day Glasgow Coma Scale (best available score in first 24 hours) \<13 * Any other circumstances that, in the opinion of the investigators, compromises participant safety

Primary outcome measure(s)

  • Positive effects — One week and one month post-dosing
    Persisting Effects Questionnaire (PEQ) - 145 questions rated using a 6-point Likert scale from 0 to 6. There are 12 sub-scale themes assessing positive and negative changes in Attitudes About Life, Attitudes About Self, Mood Changes, Social Effects, Behavioural Changes, and Spirituality. Higher scores in the positive sub-scales indicate a better outcome, while higher scores in the negative sub-scales indicate a worse outcome.

Trial sites (1)

FacilityCityRegionStatus
University of Calgary Calgary Alberta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06768944 on ClinicalTrials.gov ↗ ← All trials in Canada